HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Pegram Discusses Optimal Pertuzumab Use in HER2-Positive Breast Cancer

March 24th 2015

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.

Lapatinib Falls Short Versus Trastuzumab, Adding Clarity to Frontline HER2-Positive MBC Strategy

March 20th 2015

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast Cancer

March 11th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

February 28th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Driver Mutations Remain Prognostic But Not Predictive in Breast Cancer

February 27th 2015

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

Future Treatments for Triple-Negative Breast Cancer

February 25th 2015

Chemotherapeutics for Triple-Negative Breast Cancer

February 25th 2015

Standard Therapies for Triple-Negative Breast Cancer

February 25th 2015

Managing Brain Metastases in Breast Cancer

February 25th 2015

Role of T-DM1 in HER2-Positive Breast Cancer

February 25th 2015

Pertuzumab in HER2-Positive Metastatic Breast Cancer

February 25th 2015

BOLERO-2: Everolimus Plus Exemestane in Resistant MBC

February 25th 2015

Role of Bevacizumab in Breast Cancer

February 25th 2015

Endocrine Therapy Resistance in Breast Cancer

February 25th 2015

CDK4/6 Inhibition in Metastatic Breast Cancer

February 25th 2015

Treating ER-Positive De Novo Metastatic Breast Cancer

February 25th 2015

Genetic Tests Offer New Tool for Tumor Assessment

February 25th 2015

Pathology, Oncology Collaboration in Breast Cancer

February 25th 2015

Predicting Risk of Recurrence in Breast Cancer

February 25th 2015

Reviewing Key Genomic Assays in Breast Cancer

February 25th 2015